BioArctic AB (publ) (LON: 0RV2)

London flag London · Delayed Price · Currency is GBP · Price in SEK
197.00
-1.93 (-0.97%)
At close: Jan 21, 2025
-14.93%
Market Cap 1.28B
Revenue (ttm) 12.30M
Net Income (ttm) -17.13M
Shares Out n/a
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,111
Average Volume 5,708
Open 195.50
Previous Close 198.93
Day's Range 194.70 - 199.90
52-Week Range 9.98 - 20.77
Beta -0.25
RSI 50.57
Earnings Date Feb 13, 2025

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheim... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 88
Stock Exchange London Stock Exchange
Ticker Symbol 0RV2
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.